AdaptHealth (NASDAQ:AHCO) Given New $15.00 Price Target at Robert W. Baird

AdaptHealth (NASDAQ:AHCO) had its price objective lowered by equities researchers at Robert W. Baird from $18.00 to $15.00 in a research note issued on Monday, Marketbeat reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 39.41% from the company’s previous close.

Several other brokerages have also issued reports on AHCO. Jefferies Financial Group reaffirmed a “hold” rating and issued a $11.00 target price on shares of AdaptHealth in a research note on Monday, April 20th. Canaccord Genuity Group increased their price objective on shares of AdaptHealth from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. UBS Group reduced their price objective on shares of AdaptHealth from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Truist Financial boosted their price target on shares of AdaptHealth from $13.00 to $14.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, Royal Bank Of Canada increased their target price on AdaptHealth from $13.00 to $15.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.86.

AdaptHealth Price Performance

Shares of AHCO stock opened at $10.76 on Monday. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -17.35, a PEG ratio of 0.55 and a beta of 1.45. AdaptHealth has a 12 month low of $8.51 and a 12 month high of $13.43. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 1.21. The stock has a 50-day moving average price of $10.66 and a 200 day moving average price of $10.62.

Insider Transactions at AdaptHealth

In other AdaptHealth news, insider Russell E. Schuster III sold 11,275 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $10.06, for a total value of $113,426.50. Following the transaction, the insider directly owned 136,538 shares of the company’s stock, valued at $1,373,572.28. This trade represents a 7.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.95% of the stock is owned by insiders.

Institutional Investors Weigh In On AdaptHealth

Hedge funds have recently modified their holdings of the company. Empowered Funds LLC grew its holdings in shares of AdaptHealth by 1.4% during the first quarter. Empowered Funds LLC now owns 622,904 shares of the company’s stock worth $7,413,000 after purchasing an additional 8,602 shares during the last quarter. Quantinno Capital Management LP raised its stake in AdaptHealth by 140.0% during the first quarter. Quantinno Capital Management LP now owns 109,694 shares of the company’s stock worth $1,305,000 after buying an additional 63,992 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in AdaptHealth by 35.0% in the first quarter. Lazard Asset Management LLC now owns 1,669,454 shares of the company’s stock valued at $19,867,000 after buying an additional 432,664 shares during the period. Renaissance Technologies LLC boosted its position in AdaptHealth by 10.1% during the first quarter. Renaissance Technologies LLC now owns 228,373 shares of the company’s stock valued at $2,718,000 after acquiring an additional 21,000 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of AdaptHealth by 87.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 847,085 shares of the company’s stock worth $10,080,000 after acquiring an additional 395,668 shares in the last quarter. Institutional investors and hedge funds own 82.67% of the company’s stock.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.